Drugs / MAb 216
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00313079 | May 2006 → Feb 2009 | acute lymphoblastic leukemia | Steven E. Coutre | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAb 216 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00313079 ↗ |
| Modality | Monoclonal antibody | “a human monoclonal antibody that kills B cell acute lymphoblastic leukemia” NCT00313079 ↗ |
| Route | Intravenous | “monoclonal antibody 216 administered as an intravenous infusion” PMID 21993685 ↗ Oct 2011 |